Clinical Trial Update: Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of plasma exchange with 5% albumin for clearing beta-amyloid in cerebrospinal fluid in Alzheimer's dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Plasma exchange with 5% albumin

Snippet

Sponsor: Instituto Grifols, S.A. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-06-14